COMPASS Pathways

Update in progress

CMPS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryMedical Care Facilities

COMPASS Pathways plc is a UK-based biotechnology company focused on mental health in the UK and US. It develops COMP360, a psilocybin therapy. COMP360 is in Phase III trials for treatment-resistant depression and in Phase II trials for post-traumatic stress disorder and anorexia nervosa. It was formerly COMPASS Rx Limited, renamed COMPASS Pathways plc in August 2020, incorporated in 2020 and headquartered in London.

Company score

Sentiment: 0.26; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive